These results are not simply comparable; hence, prospective studies are needed to verify whether osimertinib or UFT is the more appropriate agent for postoperative adjuvant therapy for EGFR mutation-positive NSCLC in this pathological stage in Japan. Here, EGFR is linked to non-small cell lung carcinoma.